• 1. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 2. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Research Brief on 1-(Aminomethyl)-N-tert-butylcyclobutane-1-sulfonamide Hydrochloride (CAS: 2126162-37-4)

1-(Aminomethyl)-N-tert-butylcyclobutane-1-sulfonamide hydrochloride (CAS: 2126162-37-4) is a novel sulfonamide derivative that has recently garnered attention in the field of chemical biology and medicinal chemistry. This compound, characterized by its unique cyclobutane scaffold and sulfonamide functional group, has shown promising potential in various therapeutic applications, particularly in the modulation of protein-protein interactions (PPIs) and enzyme inhibition. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, highlighting its relevance in drug discovery and development.

The synthesis of 1-(Aminomethyl)-N-tert-butylcyclobutane-1-sulfonamide hydrochloride involves a multi-step process, starting with the cyclobutane ring formation followed by sulfonamide incorporation. The tert-butyl group enhances the compound's stability and bioavailability, while the aminomethyl moiety provides a handle for further functionalization. Recent advancements in synthetic methodologies have improved the yield and purity of this compound, making it more accessible for preclinical studies.

In terms of biological activity, 1-(Aminomethyl)-N-tert-butylcyclobutane-1-sulfonamide hydrochloride has demonstrated significant inhibitory effects on specific enzymes involved in inflammatory pathways. For instance, recent in vitro studies have shown its ability to selectively inhibit cyclooxygenase-2 (COX-2) with an IC50 value in the low micromolar range, suggesting its potential as a non-steroidal anti-inflammatory drug (NSAID) candidate. Additionally, its interaction with other molecular targets, such as G-protein-coupled receptors (GPCRs), is under investigation, with preliminary data indicating possible applications in neurological disorders.

Structural-activity relationship (SAR) studies have revealed that the cyclobutane ring and sulfonamide group are critical for the compound's bioactivity. Modifications to these moieties have led to derivatives with enhanced potency and selectivity. For example, replacing the tert-butyl group with other alkyl or aryl substituents has shown varying effects on the compound's pharmacokinetic properties, providing insights for further optimization.

Recent preclinical evaluations have also explored the compound's safety profile and toxicity. Acute toxicity studies in rodent models have indicated a favorable safety margin, with no significant adverse effects observed at therapeutic doses. However, long-term toxicity and pharmacokinetic studies are still ongoing to fully assess its suitability for clinical development.

In conclusion, 1-(Aminomethyl)-N-tert-butylcyclobutane-1-sulfonamide hydrochloride represents a promising candidate in the field of medicinal chemistry, with potential applications in inflammation and neurology. Its unique structural features and demonstrated bioactivity make it a valuable subject for further research. Future studies should focus on optimizing its pharmacokinetic properties and expanding its therapeutic indications, paving the way for potential clinical trials.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)